Clinical Trials Browser

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms, Stomach Neoplasms, Carcinoma, Merkel Cell, Neoplasms, Squamous Cell, Small Cell Lung Carcinoma

NCT02643303 2022-12-02

A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers

Phase 1/2 Completed

58 enrolled 24 charts

BreastDermatologicGenitourinaryHead & NeckLymphoidSarcoma

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Kidney Neoplasms, Melanoma, Prostatic Neoplasms, Sarcoma, Testicular Neoplasms, Carcinoma, Merkel Cell, Lymphoma, T-Cell, Cutaneous

NCT01810016 2022-10-12

NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma

Phase 1 Terminated

8 enrolled 16 charts

Dermatologic

Melanoma, Neoplasms

NCT02334735 2022-09-15

A Comparison of Matured Dendritic Cells and Montanide® in Study Subjects With High Risk of Melanoma Recurrence

Phase 2 Completed

36 enrolled

Dermatologic

Melanoma

NCT02129075 2021-11-16

A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma

Phase 2 Completed

60 enrolled 13 charts

Dermatologic

Uveal Melanoma, Melanoma

NCT02897765 2021-02-25

A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer

Phase 1 Completed

34 enrolled

DermatologicGenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Skin Neoplasms

NCT02423863 2020-12-17

Poly-ICLC

Phase 2 Completed

26 enrolled

DermatologicHead & NeckSarcoma

Head and Neck Neoplasms, Melanoma, Neoplasms, Sarcoma

NCT03597282 2020-09-03

A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma

Phase 1 Terminated

22 enrolled

Dermatologic

Melanoma

NCT01437605 2019-12-20

Phase II Study to Assess the Safety and Immunogenicity of recMAGE-A3+AS15 ASCI With or Without Poly IC:LC

Phase 2 Terminated

14 enrolled 9 charts

Dermatologic

Melanoma

NCT02061449 2018-12-24

Poly ICLC, Radiation, and Romidepsin for Advanced Cutaneous T Cell Lymphoma

Phase 1 Terminated

3 enrolled

DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous

NCT01079741 2018-02-13

Safety Study of Adjuvant Vaccine to Treat Melanoma Patients

Phase 1/2 Completed

34 enrolled 10 charts

Dermatologic

Melanoma, Neoplasms, Skin Neoplasms, Carcinogenesis

NCT02413827 2017-04-07

A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma

Phase 1/2 Terminated

9 enrolled

Dermatologic

Melanoma

NCT00948961 2016-06-27

A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1

Phase 1/2 Completed

70 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicPlasma cellSarcomaThoracic

Adenocarcinoma, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Chondrosarcoma, Esophageal Neoplasms, Melanoma, Ovarian Neoplasms, Sarcoma, Neoplasms, Plasma Cell

NCT01783431 2015-10-02

Study of Vaccination With Poly-ICLC and Peptide-pulsed Dendritic Cells

Phase 1 Terminated

1 enrolled

Dermatologic

Melanoma

NCT01008527 2015-09-24

Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100

Phase 1 Completed

22 enrolled

Dermatologic

Melanoma

NCT00553683 2014-01-14

Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver Cancer

Phase 1/2 Unknown

50 enrolled

BreastDermatologicGastrointestinalGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Colonic Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms